8-K: Lisata Therapeutics Reports Q1 2024 Financial Results and Provides Business Update, Anticipates Key Data Readouts

Lisata Therapeutics announced its first quarter 2024 financial results, highlighted by a strong start to a pivotal year with key clinical trial data expected, and reaffirmed its cash runway into early 2026.

Summary

• Lisata Therapeutics reported its financial results for the first quarter of 2024, with operating expenses totaling $6.6 million, a slight decrease from $6.8 million in the same period last year.
• Research and development expenses remained relatively stable at approximately $3.2 million, while general and administrative expenses decreased by $0.3 million to $3.4 million.
• The company's net loss for the quarter was $5.4 million, an improvement from the $6.2 million loss in the first quarter of 2023.
• As of March 31, 2024, Lisata had approximately $43.3 million in cash, cash equivalents, and marketable securities.
• The company projects that its available cash will fund operations into early 2026, covering all ongoing and planned clinical trials through to data readouts.
• Topline results from the Phase 2b ASCEND trial are expected in the fourth quarter of 2024, with the complete data set available by mid-2025.
• Lisata has received Orphan Drug and Rare Pediatric Disease designations for certepetide in osteosarcoma from the U.S. FDA.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the company's progress in clinical trials, regulatory achievements, and financial stability. However, the ongoing losses and reliance on future trial results temper the overall optimism.

Positives

• The company's net loss decreased year-over-year, indicating improved financial performance.
• Lisata has a strong cash position of $43.3 million, providing financial stability.
• The projected cash runway into early 2026 provides a solid foundation for ongoing and planned trials.
• The receipt of Orphan Drug and Rare Pediatric Disease designations for certepetide in osteosarcoma is a positive regulatory development.
• Multiple clinical trials are progressing with expected data readouts in the near future.

Negatives

• The company continues to operate at a loss, with a net loss of $5.4 million for the quarter.
• Cash reserves decreased from $50.5 million at the end of 2023 to $43.3 million as of March 31, 2024.

Risks

• The company's future success is heavily dependent on the outcome of its clinical trials, particularly the Phase 2b ASCEND trial.
• There are risks associated with regulatory approvals and the timing thereof.
• The company's ability to finance its operations and achieve future milestones is subject to market conditions and other factors.
• The company is reliant on partnerships for development and commercialization, which introduces risks related to partner performance and agreements.
• There are risks associated with the development of novel therapeutics, including the possibility that product candidates may not demonstrate safety or efficacy in later clinical trials.

Future Outlook

Lisata anticipates multiple data readouts over the next 18 months, with topline results from the Phase 2b ASCEND trial expected in the fourth quarter of 2024. The company projects its available cash will fund operations into early 2026, covering all ongoing and planned clinical trials through to data readouts.

Management Comments

• 2024, a pivotal year for Lisata, is off to a very strong start, stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata.
• Although we project multiple data readouts over the next 18 months, topline results from the Phase 2b ASCEND trial later this year have transformative potential for the Company.
• Our continued prudent financial management allows us to reaffirm our projection that currently available cash will fund operations into early 2026, providing a solid foundation to fund all ongoing and planned trials through to completion.

Industry Context

Lisata is operating in the competitive oncology therapeutics market, focusing on solid tumors with its CendR platform technology. The company's approach of enhancing drug delivery to tumors is aligned with the industry's focus on improving treatment efficacy and reducing side effects. The company is also leveraging partnerships to expand its reach and accelerate development.

Comparison to Industry Standards

• Lisata's approach of using a peptide to enhance drug delivery is similar to other companies exploring targeted drug delivery methods, such as antibody-drug conjugates (ADCs), however, Lisata's approach is unique in that it is not limited to a specific drug type.
• The company's focus on pancreatic cancer is in line with the high unmet need in this area, with companies like Halozyme Therapeutics and Rafael Pharmaceuticals also developing therapies for this indication.
• The Phase 2b ASCEND trial is comparable to other mid-stage clinical trials in terms of size and design, with the primary endpoint of progression-free survival being a common metric in oncology trials.
• Lisata's cash runway into early 2026 is a positive sign, as many biotech companies face challenges in securing funding for their development programs. Companies like Arcus Biosciences and Iovance Biotherapeutics are also focused on maintaining a strong cash position to fund their clinical programs.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the progress of clinical trials.
• Employees will be affected by the company's financial stability and future growth prospects.
• Patients with solid tumors may benefit from the development of new therapies.
• Partners will be impacted by the progress of clinical trials and the company's overall performance.

Next Steps

• Lisata will continue to enroll patients in the BOLSTER, CENDIFOX, and iLSTA trials.
• The company will report topline data from the Phase 2b ASCEND trial in the fourth quarter of 2024.
• Lisata will continue to advance its other clinical programs and explore additional partnerships.
• The company will hold a conference call to discuss the financial results and provide a business update.

Key Dates

Keywords

Certepetide, Pancreatic Cancer, Solid Tumors, Clinical Trials, Orphan Drug Designation, Rare Pediatric Disease Designation, ASCEND Trial, Financial Results, Drug Development, Oncology